Rachid Skouta completed a Ph.D. in Chemistry at McGill University in 2008 and then received a Canadian Postdoctoral Fellowship to pursue his postdoctoral training in Medicinal Chemistry and Chemical Biology at Columbia University, working with Professors Ronald Breslow and Brent Stockwell. Currently, he works in the research faculty in the Department of Biology at the University of Massachusetts-Amherst. One of his sustained records of accomplishment in the field is the design and synthesis of specific small-molecule inhibitors of ferroptosis. He has published more than 43 peer-reviewed papers and filed five patents in drug discovery. One of these patents focuses on the creation of a novel ferroptosis inducer (Sorafenib) and two relate to the design and creation of ferroptosis inhibitors (ferrostatin-1). His research lab focuses on developing natural and non-natural bioactive compounds that trigger well-programmed cell death, such as ferroptosis and apoptosis, using medicinal chemistry tools. He is currently seeking collaborations with medical doctors, clinicians, and researchers to evaluate his lab’s promising compounds in various biological models.